| 1. |
- Allgulander, Christer, et al.
(författare)
-
Efficacy of venlafaxine ER in patients with social anxiety disorder : A double-blind, placebo-controlled, parallel-group comparison with paroxetine
- 2004
-
Ingår i: Human Psychopharmacology. - : Wiley. - 0885-6222 .- 1099-1077. ; 19:6, s. 387-396
-
Tidskriftsartikel (refereegranskat)abstract
- This study evaluated the anxiolytic efficacy, safety and tolerability of a flexible dose of venlafaxine extended release (ER) compared with placebo and paroxetine in the short-term treatment of generalized social anxiety disorder (SAD). Adult outpatients with generalized SAD (n=434) were randomized to receive capsules of venlafaxine ER 75 mg to 225 mg/day, paroxetine 20 mg to 50 mg/day, or placebo for 12 weeks. The primary efficacy variable was the Liebowitz social anxiety scale total score. Secondary efficacy variables included the patient-rated social phobia inventory and the proportion of responders in each group (a responder was defined as having a clinical global impression-improvement score of 1 or 2). Treatment with venlafaxine ER was associated with significantly greater improvement than treatment with placebo for all primary and secondary efficacy variables (p<0.05). No significant differences in primary or secondary efficacy variables were observed between the venlafaxine ER and paroxetine groups. The week 12 response rates were 69%, 66% and 36% for the venlafaxine ER, paroxetine and placebo groups, respectively. Both active treatments were generally well tolerated and were associated with a similar incidence of adverse events. This study shows that venlafaxine ER is an effective, safe and well-tolerated drug treatment for SAD.
|
|
| 2. |
- Knott, V.J., et al.
(författare)
-
Acute cholecystokinin effects on event-related potentials in healthy volunteers
- 2002
-
Ingår i: Human Psychopharmacology. - : Wiley. - 0885-6222 .- 1099-1077. ; 17:6, s. 285-291
-
Tidskriftsartikel (refereegranskat)abstract
- This study investigated the effects of a continuous slow infusion of cholecystokinin tetrapeptide (CCK-4), a neuropeptide with panicogenic properties, on brain event-related potentials (ERPs) in healthy adults. Twenty-four volunteers, 15 females and 9 males, were assigned to infusion with either placebo or CCK-4 in a randomized, double-blind, parallel group design. ERPs, elicited within a standard auditory odd-ball paradigm requiring the counting of rare (20%) occurring 'deviant' tones interspersed among more frequent (80%) occurring 'standard' tones, were assessed once before infusion, and at 10 min and 40 min after the onset of infusion. Compared with the placebo, CCK-4 delayed the latencies of N100 and P200 components elicited by 'deviant' stimuli. No significant treatment differences were observed with respect to N200, P300b, mood or adverse symptoms. These preliminary findings suggest that CCK-4 may interfere with information processing relating to the selection of significant stimulating and as such, may be of relevance to mechanisms underlying panic disorder. Copyright © 2002 John Wiley & Sons, Ltd.
|
|
| 3. |
- Phol, Annika, et al.
(författare)
-
Clinical and biochemical observations during treatment of depression with electroacupuncture : A pilot study
- 2002
-
Ingår i: Human Psychopharmacology. - : Wiley. - 0885-6222 .- 1099-1077. ; 17:7, s. 345-348
-
Tidskriftsartikel (refereegranskat)abstract
- Six patients suffering from major depression were treated with electroacupuncture. During 4 weeks of treatment, the total CPRS-S-A score decreased from 23.8 to 13.4 (p = 0.0095). A decrease of neuropeptide Y (NPY) in plasma during the first 2 weeks of treatment was noted in five of the patients, all being women (p = 0.0431). The decrease was negatively correlated with age (rs = -0.29, p = 0.046). The results are in line with a putative antidepressive effect of electroacupuncture, along with an influence on NPY in plasma. Copyright ⌐ 2002 John Wiley & Sons, Ltd.
|
|
| 4. |
- Reis, Margareta, et al.
(författare)
-
Serum disposition of sertraline, N-desmethylsertraline and paroxetine : a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression
- 2004
-
Ingår i: Human Psychopharmacology. - : Wiley. - 0885-6222 .- 1099-1077. ; 19:5, s. 283-291
-
Tidskriftsartikel (refereegranskat)abstract
- Sertraline and paroxetine are frequently prescribed SSRIs for long-term treatment of major depression. Nevertheless, continuous follow-ups of drug concentrations prevailing in patients during the whole treatment period are not available. Hence, in a large phase IV clinical trial, a total of 353 patients with major depression were enrolled for a 6-month comparison of sertraline (50–150 mg daily) and paroxetine (20–60 mg daily). The present study reports the pharmacokinetic results of up to eight serum samples per patient.1 A profound variability was found in the interindividual steady state and trough serum levels of sertraline, desmethylsertraline and paroxetine: the coefficient of variation (CV) was 59% for sertraline, 51% for desmethylsertraline, 27% for the ratio desmethylsertraline/sertraline (50 mg/day), and 71% for paroxetine (20 mg/day). The intraindividual CV for the ratio desmethylsertraline/sertraline was only 19%, indicating intraindividual metabolizing stability over time. Both sertraline and paroxetine displayed sex differences in the dose-concentration correlation.2 It was possible to predict sertraline, but not paroxetine, steady state levels.3 The terminal elimination t½ for both drugs after 6 months of treatments was similar to data previously reported from short-term withdrawal studies.4 No correlation between serum drug concentrations and clinical effect was detected for either sertraline or paroxetine.For the future, continuous efforts are warranted to perform PK investigations in the natural clinical setting in which the drugs are usually prescribed.
|
|
